Anzupgo FDA Approval History
Last updated by Judith Stewart, BPharm on July 23, 2025.
FDA Approved: Yes (First approved July 23, 2025)
Brand name: Anzupgo
Generic name: delgocitinib
Dosage form: Topical Cream
Company: LEO Pharma Inc.
Treatment for: Eczema
Anzupgo (delgocitinib) is a topical pan-Janus kinase (JAK) inhibitor for the treatment of chronic hand eczema.
- Anzupgo is indicated for the topical treatment of moderate to severe chronic hand eczema (CHE) in adults who have had an inadequate response to, or for whom topical corticosteroids are not advisable.
- Use of Anzupgo in combination with other JAK inhibitors or potent immunosuppressants is not recommended. - Chronic hand eczema (CHE) is defined as hand eczema that lasts for more than three months or relapses twice or more within a year. It is characterized by itch and pain, and some patients can also experience erythema, scaling, lichenification, hyperkeratosis, vesicles, edema, and fissures on hands and wrists.
- Anzupgo works by inhibiting the activation of JAK-STAT signaling, which plays a key role in the pathogenesis of CHE.
- Anzupgo cream is applied twice daily to the skin of the affected areas only on the hands and wrists. Patients should not use more than 30 grams per 2 weeks or 60 grams per month.
- Warnings and precautions associated with Anzupgo include an increased risk of infection and non-melanoma skin cancers.
- Reported adverse reactions (≤ 1% of subjects) include application site pain, paresthesia, pruritus, erythema, and bacterial skin infections including finger cellulitis, paronychia, other skin infections, leukopenia, and neutropenia.
Development timeline for Anzupgo
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.